CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

UBS Adjusts First Tracks Biotherapeutics PT to $65 From $45, Maintains Buy Rating

Positive
AI Analysis

Summary

UBS raised its price target for Tracks Biotherapeutics from $45 to $65 while maintaining a Buy rating, reflecting increased valuation expectations for the company.

Importance:3/10
Sentiment:
0.60
price_target_increaseanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on August 10, 2026 1:29 PM

Read Original